Becton Dickinson and Company (BDX) has attracted significant interest from a diverse group of investors.
CreativeOne Wealth LLC, Canada Pension Plan Investment Board, Advisory Services Network LLC, Empowered Funds LLC, State Board of Administration of Florida Retirement System are increasing their position, while others like
First Foundation Advisors, Choate Investment Advisors are reducing theirs. The company has a strong partnership network, including a collaboration with
Quest Diagnostics (DGX) to develop companion diagnostics for cancer, leading to raised price targets. Becton Dickinson's board has declared dividends and has raised its fiscal 2024 guidance with Q2 earning beating estimates. The firm addressed significant challenges, such as a supplier issue impacting blood culture vials and safety communication concerning BD syringes. Becton Dickinson made substantial investments, like the acquisition of
Edwards Lifesciences' Critical Care Product Group for $4.2 billion. These steps are demonstrated in their surpassing Scope 1 and 2 reduction milestones for FY 2023. However, the company endured losses, such as a decline after lower-than-expected 2024 guidance. Moving forward, challenges related to debt and a recent increase in short interest will need to be addressed.
Becton Dickinson and BDX News Analytics from Thu, 09 Nov 2023 08:00:00 GMT to Sun, 28 Jul 2024 16:00:24 GMT -
Rating 5
- Innovation 7
- Information 6
- Rumor 3
